Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Seer, Inc.NASDAQ: SEER

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $9.43M fell 17.6% year over year, ahead of the -24.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.0% from the prior quarter. Over 3 fiscal years it compounded at -6.8% a year.

Context

  • Selling, general & admin amounted to 264.2% of revenue in FY2025, down 141.4 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $62.81M (+47.5%) for the fiscal year ending Dec 2026, a step up from the -24.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.43M-4.0% QoQ
Last fiscal yearDec 2025
$42.58M-24.7% YoY
LTMMar 2026
$40.57M-24.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.6%+38.4%+55.9 pp
1 year-24.7%+47.5%+72.2 pp
3-year CAGR-6.8%+32.2%+39.0 pp
5-year CAGR+35.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
42.58M USD
Year-over-year change
-24.7%
4-year CAGR
+0.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -24.5% is the 18th highest of 19, against a peer median of -3.7%.
  • Selling, general & admin amounts to 269.8% of revenue for SEER, versus a peer median of 98.7%.
SEER Competitors
Selling, General & Admin for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MNOVMediciNova, Inc.LTM Mar 2026$1.59B USD+28956.6%+3.9%267325.2%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$78.21M USD+57.0%+11.6%11.1%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$75.77M USD+15.3%+15.9%72.2%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$69.2M USD+144.0%+94.7%—
PHVSPharvaris N.V.LTM Sep 2026€61.14M EUR+31.2%+15.6%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$52.28M USD-5.2%+10.5%—
SANASana Biotechnology, Inc.LTM Mar 2026$44.27M USD-25.3%-14.8%—
QSIQuantum-Si incorporatedLTM Mar 2026$42.51M USD-16.5%+1.9%2295.5%
LYELLyell Immunopharma, Inc.LTM Mar 2026$40.64M USD-22.7%-27.3%131109.7%
SEERSeer, Inc.LTM Mar 2026$40.57M USD-24.5%-6.8%269.8%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$37.85M USD+8.5%+10.0%88.1%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$34.4M USD-16.4%-5.4%98.7%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$33.29M USD+12.6%+9.8%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$26.89M USD-3.6%-3.6%95.3%
NKTXNkarta, Inc.LTM Mar 2026$25.06M USD-19.7%+4.0%—
PEPGPepGen Inc.LTM Mar 2026$22.56M USD+1.9%+16.6%—
STTKShattuck Labs, Inc.LTM Mar 2026$17.37M USD-6.9%-4.3%1736.5%
MOLNMolecular Partners AGLTM Mar 2026CHF 16.11M CHF-3.8%-12.0%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$13.3M USD-6.8%+1.5%—
Peer median (excluding SEER) —-3.7%+4.0%98.7%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.